Am J Transplant, Volume 18, Suppl 3 Archives - Page 12 of 211 - ATC Abstracts

2018 American Transplant Congress
Geographic Variation in the Treatment of Adult Heart Transplant Candidates in the US
W. Parker,¹ M. Churperk,¹ D. Hedeker,¹ E. Huang,¹ E. Garrity,¹ M. Siegler,¹ A. Anderson.²
¹University of Chicago, Chicago, IL; ²Northwestern University, Chicago, IL.
The current priority ranking system for US heart transplant candidates is based on treatment intensity which may encourage the overtreatment of relatively stable candidates. We…
2018 American Transplant Congress
Lymphocyte Proportions Post Thymectomy Are Associated with Allergic Disorders in Heart Transplanted Children
T. Kim,¹ L. Ionescu,^1,2,3 N. Avdimiretz,⁴ M. Larsen,^1,2,3 F. Murdoch,^1,2 B. Motyka,^1,2,3 S. Gilmour,^1,2 L. West,^1,2,3 S. Urschel.^1,2,3
¹Pediatrics, University of Alberta, Edmonton, AB, Canada; ²Stollery Children's Hospital, Edmonton, AB, Canada; ³Alberta Transplant Institute, Edmonton, Canada; ⁴The Hospital for Sick Children, Toronto, Canada.
Background: Allergic disorders are more common in pediatric heart transplant (HTx) recipients than non-transplanted children, with young age at HTx and thymectomy being risk factors.…
2018 American Transplant Congress
Combined Heart–Kidney Compared to Isolated Heart Transplant in Patients with Chronic Kidney Disease – A Single Center Experience
D. Gauvin, A. Bhalla, W. McCallum, A. Vest, N. Goyal.
Tufts University School of Medicine, Boston, MA.
Background: Severe irreversible renal dysfunction has been a contraindication for heart transplant (HTx); however, combined heart-kidney transplant (HKTx) is an accepted therapeutic option for concomitant…
2018 American Transplant Congress
Analysis of Human Islet Damage during In Vitro Culture Using miRNA 375
Y. Shindo,¹ M. Levy,^1,2 M. Kanak.¹
¹Department of Surgery, School of Medicine, Virginia Commonwealth University, Richmond; ²Hume-Lee Transplant Center, VCU Health System, Richmond.
BackgroundIslet culture prior to transplantation has been shown to facilitate recovery, reduce immunogenicity, suppress exocrine contamination and provides flexibility for evaluation of islets and preparation…
2018 American Transplant Congress
DonorNet and Biases in Decision-Making: An Organ Offer Simulation Study
D. Stewart,¹ J. Lindemans,² J. Schold,³ H. McGehee,¹ J. Kessler,⁴ C. Sullivan,⁴ M. Turner,² K. Mekeel,⁵ C. Berg,² R. Stratta,⁶ R. Formica,⁷ L. Ratner,⁸ D. Klassen,¹ B. Shepard.¹
¹UNOS, Richmond; ²Duke, Durham; ³CCF, Cleveland; ⁴Wharton, Philadelphia; ⁵UCSD, San Diego; ⁶Wake Forest, Winston-Salem; ⁷Yale, New Haven; ⁸Columbia, NY.
Background: Behavioral science research has revealed that the way information is presented can impact decision-making. UNOS has developed a DonorNet-like simulation tool to send hypothetical…
2018 American Transplant Congress
Early Outcomes and Risk Factors after Five Years of a Nationwide Strategy for Kidney Transplantation with Controlled Circulatory Death Donor (cDCD)
J. Portoles,^1,2 M. Perez Saez,² D. Hernandez,² J. Juega,² F. Moreso,² N. Maruri,² P. Lopez,^1,2 E. Melilli,² D. Navarro,² E. de Souza,² J. Ruiz,² M. Mazuecos,² A. Gutierrez,² I. Perez-Flores,² D. Janeiro,^1,2 J. Pascual.²
¹Nephrology, H Puerta de Hierro, Madrid, Spain; ²Nephrology, Spanish Multicentre Sentra-GEODAS Group, Madrid, Spain.
Study: prospective multicentre, systematic inclusion of every kidney transplants-KTx from controlled donation after circulatory death (cDCD) at joined units. Local center surgical and immunosuppressive protocols.Background:…
2018 American Transplant Congress
Differences in Rejection and Clinical Outcomes in Obese versus Non-Obese Renal Transplant Recipients Receiving Basiliximab Induction Immunosuppression
J. Benken,¹ C. Kane,² A. Lichvar,¹ E. Benedetti.¹
¹University of Illinois at Chicago, Chicago, IL; ²University of Northwestern Memorial Hospital, Chicago, IL.
Introduction: Basilixiab is a fixed-dose IL-2 receptor antagonist that is used for non-lymphodepleting induction therapy. The impact of obesity on basiliximab pharmacokinetics and pharmacodynamics is…
2018 American Transplant Congress
Anti-Thymocyte Globulin vs. Alemtuzumab: A Comparison of Long-Term Outcomes among Renal Transplant Recipients
E. Loncharic, A. Dodson, K. Gutierrez.
Department of Pharmacy, The University of Alabama at Birmingham, Birmingham, AL.
Background: Two lymphocyte depleting agents are currently available for renal transplant induction: alemtuzumab (C1H) and rabbit anti-thymocyte globulin (rATG). Studies comparing long-term outcomes between C1H…
2018 American Transplant Congress
Long-Term Follow Up of Living Kidney Donors with CKD at 1 Year after Nephrectomy
J. Na,¹ J. Park,¹ M-.G. Yoon,¹ H. Lee,² Y. Yoon,³ K. Huh,⁴ M. Kim,⁴ S. Kim,⁴ Y. Kim,⁴ W. Han.¹
¹Department of Urology, Yonsei University College of Medicine, Urological Science Institute, Seoul, Korea; ²Department of Urology, National Health Insurance Service Ilsan Hospital, Goyang-si, Korea; ³Department of Urology, Hanyang University Medical Center, Seoul, Korea; ⁴Department of Surgery-Transplantation, Yonsei University College of Medicine, Seoul, Korea.
Introduction:Many kidney donors show poor recovery after donation and the long-term prognosis of those patients has not been well studied. In this study we explored…
2018 American Transplant Congress
Kidney Transplant Outcome in the Patients with Lupus Nephritis
Y. Kim,¹ H. Lee,¹ H. Chin,² Y. Kim,^3,4 S. Han.¹
¹Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; ²Internal Medicine, Seoul National University Bundang Hopsital, Seong-Nam, Republic of Korea; ³Medical Science, Seoul National University College of Medicine, Seoul, Republic of Korea; ⁴Kidney Research Institute, Seoul National University, Seoul, Republic of Korea.
Background: Despite improvements in overall prognosis in lupus nephritis, 10%-30% of patients with proliferative renal involvement progress to end stage renal disease, and kidney transplantation…